Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study

BACKGROUND: Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD), but currently available treatments do not improve kidney function or prevent the initiation of dialysis/kidney replacement therapy. A previous study demonstrated that bardoxolone methyl improves the es...

Descripción completa

Detalles Bibliográficos
Autores principales: Nangaku, Masaomi, Takama, Hirotaka, Ichikawa, Tomohiro, Mukai, Kazuya, Kojima, Masahiro, Suzuki, Yusuke, Watada, Hirotaka, Wada, Takashi, Ueki, Kohjiro, Narita, Ichiei, Kashihara, Naoki, Kadowaki, Takashi, Hase, Hiroki, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157761/
https://www.ncbi.nlm.nih.gov/pubmed/36002026
http://dx.doi.org/10.1093/ndt/gfac242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157761/
https://www.ncbi.nlm.nih.gov/pubmed/36002026
http://dx.doi.org/10.1093/ndt/gfac242

Ejemplares similares